<DOC>
	<DOCNO>NCT01573572</DOCNO>
	<brief_summary>Due lack information generate pivotal phase III trial assess potential effect intravitreal injection Macugen ( pegaptanib sodium injection ) corneal endothelium , FDA request clinical information 1-year ( minimum ) clinical study support adverse effect corneal endothelium follow intravitreal injection Macugen .</brief_summary>
	<brief_title>Continuation Previous Study Gather More Data Effect Macugen Corneal Endothelium</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>1 . Subjects either gender age &gt; = 50 year diagnose subfoveal neovascular AgeRelated Macular Degeneration , Diabetic Macular Edema , Retinal Vein Occlusion . 2 . Best correct visual acuity study eye 85 20 ETDRS letter 20/20 20/400 use Snellen chart . 3 . Women must use two form effective contraception , postmenopausal least 12 month prior study entry , surgically sterile ; childbearing potential , urine pregnancy test must perform within 7 day prior first injection negative result . If test positive , serum test must do confirm . The two form effective contraception must implement study least 60 day follow last dose test medication . 4 . Provide write informed consent . 5 . Ability return study visit . Subjects eligible study subject attend studyrequired visit , follow criterion present 1 . Unilateral ocular blunt trauma within one year enrollment great 5 % difference central endothelial cell density 2 eye . 2. intraocular surgery ( cataract surgery surgery glaucoma without tube shunt minishunt ) within one year enrollment . 3 . Anterior segment laser surgery ( laser trabeculoplasty ) perform within one year enrollment . 4 . Glaucoma tubeshunt surgery 5 . Previous history corneal transplant study nonstudy eye 6 . Presence vitreous macular traction 7 . Previous therapeutic radiation region study eye 8 . Any treatment investigational agent past 30 day condition 9 . Known serious allergy component pegaptanib sodium formulation Any follow underlying disease including:1 . History evidence severe cardiac disease ( e.g . NYHA Functional Class III IV see Appendix 2 ) , clinical medical history unstable angina , acute coronary syndrome , myocardial infarction revascularization within 6 month , ventricular tachyarrhythmias require ongoing treatment 7 . History evidence clinically significant peripheral vascular disease , intermittent claudication prior amputation 8 . History evidence clinically significant impaired renal hepatic function 8 . Stroke ( within 12 month study entry ) 9 . Any major surgical procedure within one month study entry 10 . Significant medium opacity , include cataract , might interfere visual acuity , assessment toxicity . Subjects enter likelihood require cataract glaucoma surgery either eye study treatment followup period .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>